CRC for Interstitial Lung Disease

The Major Challenge

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic Interstitial Lung Diseases (ILDs), and the reported incidence is likely to be >10/100,000 and with an aging population, this figure will increase rapidly.

Little is known about the incidence or prevalence of IPF in Australia. No single Australian Centre has an adequate patient population to facilitate robust research. A coordinated, multi-centred approach will remedy this and place Australia as a significant partner in future clinical trials for IPF therapy.

The CRC for Interstitial Lung Disease will follow a staged-strategy leading to a step-change in understanding IPF/ILD pathogenesis and drug development.


Anticipated Bid Round

 18th Selection Round (2015).


Contacts

Professor Darryl Knight
Head of School,
School of Biomedical Sciences and Pharmacy
T: +61 2 4921 7485
E: Darryl.Knight@newcastle.edu.au
Angela Gray
Research Development Officer
Research Development Unit
T: +61 2 4921 6064
E: Angela.Gray@newcastle.edu.au